Projects

1.   5PO1CA229100:              Overall PI: Liza Rimsza                              09/19/2018 –8/30/2023 (NCE)
Funding: DHHS/NIH/NCI
Molecular Pathogenesis of two newly defined major subgroups of PTCL Peripheral T-cell lymphoma (PTCL) is a heterogenous group of lymphomas with 30-50% remains unclassifiable (PTCL-NOS). We have delineated two novel biological and prognostic subgroups within PTCL-NOS. We will perform extensive genomic characterization of these novel PTCL subgroups, generate genetically faithful murine models and develop patient derived xenograft models for novel therapeutic approaches in PTCL (Co-PI: Iqbal, Chan)

2.   1R01CA251412-01A1         (Iqbal)             09/01/2021 – 06/30/2026                          2.4 calendar
DHHS/NIH
Cooperative role of TET2 & IDH2 mutation in Angioimmunoblastic T-Cell LymphomagenesisTo delineate role of TET2 and IDH2R172 mutation in AITL using murine models.

3.   1U01CA253218A1 (Iqbal)                    09/01/2021 – 06/30/2026                                  1.80 calendar
DHHS/NIH
Pre-analytical variables of bioanalyte affecting the accuracy of PTCL diagnostic and prognostic genetic signatures. Development of PTCL diagnostic assay and CT-DNA analysis for wider clinical use 

4.   CA210960                (Iqbal)                  08/02/2022-  8/31/2027                     2.4 calendar 1.20 calendar
U.S. Department of Defense CDMRPPeer Reviewed Cancer Research Program: Translational Team Science Award  Genomic Biomarker-Driven Treatment Strategy in PTCL  To use DNA /RNA from tissue biopsies and corresponding circulating tumor DNA in blood plasma of the PTCL for accurate diagnosis and disease monitoring. To facilitate personalized therapy and improve patient outcomes using this “liquid biopsy” and to advance the standard-of-care for treatment of PTCL subtypes in the relapsed/refractory setting.

5.   1R01CA266612-01 (MPI: Iqbal/Orlowski) 08/01/2022 – 08/31/2027
MD Anderson Cancer CenterRole of Heat Shock Protein 70 as a Mediator and Therapeutic Target in T-cell Lymphomas
To investigate the role of HSP70 targeted ADCC therapy in T-cell lymphomas 

6.   1R01CA266544-01 (PI: Merchant) 08/01/2022 – 08/31/2027    (Co-I: Iqbal)                    Cedars-Sinai Medical Center
Non-federal funding ( NE state level)
Spatially resolved, single cell biomarkers of B cell lymphomaTumor microenvironment analysis in DLBCL using CyTOF analysis

7.   NE DHHS – LB506 (Iqbal)                                       07/01/2021 – 06/30/2022
Delineating epigenetic reprogramming in Angioimmunoblastic T-cell lymphoma using murine modelsTo develop triple mutant murine models (TET2, IDH2R172K and DNMT3A) to delineate the role of epistasis mutations in T-cell pathogenesis

PENDING – SUBMITTED

PO1# 1610406 (resubmission)           Overall PI: Feldman A and Scott D.               09/19/2024 –8/30/2029
Molecular Diagnosis, Prognosis, and Therapeutic Targets in Lymphoma
DHHS/NIH/NCI
Project 3 PI (Iqbal)  – Molecular Pathogenesis of two newly defined n-TFHLsWe will perform extensive genomic characterization of these novel PTCL subgroups, generate genetically faithful murine models and develop patient derived xenograft models for novel therapeutic approaches in PTCL.

Completed Research Support 

Roswell Park Cancer Institute                                         Fu (PI)
Targeting PLK-1 for Treating MYC-Driven LymphomasWe propose to identify the role of PLK1 in upregulating MYC expression in aggressive lymphomas.

Industry sponsored projects
Kymera Therapeutics, Inc. (Iqbal)
Therapeutic efficacy of degrading Stat3 in PTCLs 

Leidos Biomedical Research, Inc. (Iqbal).   08/14/2020 – 06/30/2023
Subcontract with Leidos Biomedical Research 19X121Q  TCGA-like sequencing project (PTCLs n=500).  We propose to perform high throughput genomic sequencing on well characterized PTCL cases collected over several clinical centers. 

5UH3CA206127-04 (Iqbal)                 04/01/2017 – 08/31/2022 (NCE)                           1.20 calendar
DHHS/NIH/NCI
We proposed to translate the diagnostic and prognostic signatures for PTCL into a platform that can be used robustly on paraffin embedded tissue in routine clinical practice and clinical trials.
Molecular diagnostic signatures for PTCL

NE DHHS – LB506 (#22051)                                      Iqbal (PI)                                       2018-2019
Role of Epigenomic Modifiers in AITL pathogenesis (tumor microenvironment)

2021-05 (Bhatt). 2020 – 2021
NE DHHS – LB506
ONC201 maintenance after hematopoietic stem cell transplantTo monitor NK cell gene expression changes post HSCT and ONC201 treated AML patients 

UN Foundation                                                           Iqbal (PI)                                                          2018-2019
Role of Concurrent Loss of TET2 Function and Neomorphic Activity in IDH2 in the AITL Pathogenesis

R41CA221466-01A1                                                  Morris S/Iqbal (MPI)                                             2018-2019
Development of a Novel Clinical Diagnostic Assay for Peripheral T-cell Lymphoma (PTCL) 

Lymphoma Research Foundation (LRF)                          Iqbal (PI)                                                   2013-2015
Somatic mutations in the pathogenesis of angioimmunoblastic T- cell lymphoma (AITL)
The goal of this study is to identify mutations that are involved in pathogenesis of AITL 

Leukemia & Lymphoma Society (LLS: The Translational Research Program)       Iqbal (PI)          2013-2016 
Somatic mutations and epimutations in Peripheral T-cell Lymphoma 
The goal of this study is to perform next generation sequencing in PTCLs to identify driver mutations 

NTSBRDF Iqbal (PI) 2013-2014
Synergism of PRDM1 Loss and LMP1 Expression in NK cell Lymphoma genesis.

U01-CA-114778-05                                    Chan (PI)                                                                          2005-2010
Molecular Signatures to Improve Diagnosis and Outcome Prediction in NHL
The goal of this study is to identify molecular signatures for major B-cell lymphomas 
Role: Co-Investigator